Bayer, Gets

Bayer Gets a Court-Backed Ceiling on Roundup Claims While Two Brokers Rework Their Math

Published on 11/22/2026 at 14:41 | Editorial boerse-global.de
A Missouri court gave final approval to Bayer's Monsanto glyphosate settlement, capping exposure at up to $7.25 billion; two brokers raised Bayer price targets.
Bayer, Gets, Court-Backed, Ceiling, Roundup, Claims, While, Two, Brokers, Rework Illustration mit AI erstellt.

A Missouri court on Friday gave final approval to Monsanto's blanket settlement of glyphosate litigation, capping the Bayer subsidiary's exposure at as much as $7.25 billion — a figure that includes money already paid out. The ruling is subject to appeal, Bayer said.

The payout structure stretches across as many as 21 years and resolves thousands of claims tied to Roundup, the weedkiller at the center of the litigation, according to Reuters. Bayer called the approval a milestone in its push to contain both pending and potential future cases.

Investors greeted the decision in after-hours Tradegate trading, where the stock initially added 3%. By the close of Friday's regular session, Bayer shares were up 1.2% at €55.16.

Should investors sell immediately? Or is it worth buying Bayer?

Two brokers, two targets, one shared theme

The legal news landed in the same week that two research houses lifted their price targets on the stock. Kepler Cheuvreux raised its target to €68 from €59 on Thursday and kept its buy rating. Berenberg had moved first, lifting its target to €62.00 from €53.50 on Wednesday and sticking with its hold recommendation.

Analyst Sebastian Bray, who authored the Berenberg note, pointed to the momentum in the pharmaceuticals division and to the prospect of proceeds from a Monsanto initial public offering toward the end of the decade. In his view, cash raised from such a listing could be channeled into drug development.

A first-in-class approval

The pharma pipeline delivered its own headline during the week. The FDA cleared Bayer's Asundexian, to be marketed as Sunharbo, for reducing the risk of recurrent strokes in the United States. Bayer described the drug as the world's first approved factor XIa inhibitor.

That approval, the analyst upgrades and the settlement ruling all arrived within days of one another — a run that gave the shares their first sustained lift in some time. Whether the momentum holds may depend on how the appeals process plays out and on how quickly the pharma business can convert pipeline wins into revenue.

Ad

Bayer Stock: New Analysis - 22 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70544482 |